Naloxegol US PMR CV Safety.
Public ClinicalTrials.gov record NCT02813356. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
United States Post-Marketing Observational Cardiovascular Safety Study in Patients Taking Naloxegol
Study identification
- NCT ID
- NCT02813356
- Recruitment status
- Not listed
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Valinor Pharma LLC
- Industry
- Enrollment
- 8,800 participants
Conditions and interventions
Conditions
Interventions
- naloxegol Drug
- non-PAMORA Drug
Drug
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 23, 2016
- Primary completion
- Dec 30, 2023
- Completion
- Dec 30, 2023
- Last update posted
- May 14, 2023
2016 – 2023
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Wilmington | Delaware | 19803 | — |
| Research Site | Hines | Illinois | 60141 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02813356, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2023 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02813356 live on ClinicalTrials.gov.